Letter: Hepatitis B and MAFLD ‐ a consilience of risk factors for hepatocellular carcinoma

Zheng, Kenneth I.; Zheng, Ming‐Hua

doi:10.1111/apt.16532

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accompanied by the rapid increase in the prevalence of metabolic disorders, the coexistence of metabolic syndrome and CHB is commonly observed. [9][10][11] In hepatitis B virus (HBV) carriers, metabolic factors such as obesity and diabetes are well-established risk factors for HCC; however, hepatitis steatosis is found to be associated with a lower incidence of HCC. 12 Thus, owing to the combined effects of these metabolic factors, MAFLD represents a complex multisystem disorder, and the impact of MAFLD on the clinical outcomes of CHB-HCC patients remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease

You¹,

Yang²,

Wei³

et al. 2023

DMSO

View full text Add to dashboard Cite

Metabolic associated fatty liver disease is a novel concept defined as fatty liver associated with metabolic disorders. We investigated the effect of metabolic associated fatty liver disease on hepatocellular carcinoma patient mortality. Patients and Methods: A total of 624 patients with hepatocellular carcinoma between 2012 and 2020 were enrolled in this retrospective study. Hepatic steatosis was diagnosed using computed tomography or magnetic resonance imaging. Metabolic associated fatty liver disease was defined based on the proposed criteria in 2020. Propensity score matching was performed for patients with metabolic associated fatty liver disease and those without the condition. A Cox proportional hazards regression model was used to evaluate the association between metabolic associated fatty liver disease and hepatocellular carcinoma patient outcomes. Results: Patients with hepatocellular carcinoma and metabolic associated fatty liver disease tended to achieve better outcomes than did those without metabolic associated fatty liver disease after matching (p<0.001). Metabolic associated fatty liver disease was significantly associated with better prognosis in patients with concurrent hepatitis B infection (p<0.001). Moreover, high levels of hepatitis B viral DNA in serum samples was associated with a significantly increased risk of death in patients without non-metabolic associated fatty liver disease (p=0.045). Additionally, the association between metabolic associated fatty liver disease and survival in hepatitis B virus-related hepatocellular carcinoma was similar in all subgroups based on metabolic traits. Conclusion: Metabolic associated fatty liver disease increases the survival rate of patients with hepatocellular carcinoma and hepatitis B virus infection. The potential interaction of steatosis and virus replication should be considered for future research and clinical treatment strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease

You¹,

Yang²,

Wei³

et al. 2023

DMSO

View full text Add to dashboard Cite

show abstract

Prevalence and risk factors of significant fibrosis in CHB patients with concurrent MASLD

Hong,

Hao,

Sun

et al. 2024

Annals of Hepatology

View full text Add to dashboard Cite

Letter: Hepatitis B and MAFLD ‐ a consilience of risk factors for hepatocellular carcinoma

Abstract: LINKED CONTENTThis article is linked to Estes et al paper. To view this article, visit https://doi.org/10.1111/apt.15673

Cited by 2 publications

References 10 publications

Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease

Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease

Prevalence and risk factors of significant fibrosis in CHB patients with concurrent MASLD

Contact Info

Product

Resources

About